Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex (NCT07756138)
A Pilot Trial to Evaluate the Efficacy and Safety of Filsuvez in the Treatment of Moderate-to-Severe Epidermolysis Bullosa Simplex
🩺 Plain-English Summary (8th-Grade Level)
This pilot study will look at whether the topical Birch Triterpenes (Filsuvez) gel is safe and helpful for adults and children 6 months of age and older who have moderate to severe epidermolysis bullosa simplex (EBS). The study will examine whether the gel can reduce the number of blisters, help wounds heal faster, and improve comfort by reducing pain and itching and making daily activities easier.
Who can join: Review the eligibility criteria below.
Location: Stanford University School of Medicine — Palo Alto, California
Age range: 6 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Stanford University School of Medicine — Palo Alto, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epidermolysis Bullosa Simplex
Explore by condition: All Epidermolysis Bullosa Simplex clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.